IP Library Patent Application 14671251
Patent Application
App. No. 14/671,251

PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL -1-PHENYL-2-(1H)-PYRIDONE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/671,251
Abstract

A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.

Claims (14)

1 . A tablet containing as the main ingredient 5-methyl-1-phenyl-2-(1H)-pyridone.

2 . A tablet as claimed in claim 1 , the weight of which is 100 to 1000 mg.

3 . A tablet as claimed in claim 1 or 2 , which contains 10 to 85 wt. % main ingredient to the weight of the tablet.

4 . A tablet as claimed in any one of claim 1 to 3 , wherein the content of the main ingredient is 200 mg to 400 mg.

5 . A tablet as claimed in any one of claim 1 to 4 , which contains a light-shielding agent.

6 . A tablet as claimed in claim 5 , which contains 0.05 to 3 wt. % shielding agent based on the main ingredient.

7 . A tablet as claimed in any one of claim 1 to 4 , which contains 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent based on the main ingredient.

8 . A tablet as claimed in claim 7 , which contains 0.01 to 1 wt. % plasticizer based on the main ingredient.

9 . A tablet as claimed in any one of claim 1 to 4 , which consists of a plain tablet containing 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, and 0.5 to 5 wt. % lubricant on the main ingredient, and coating layer containing 2 to 6 wt. % coating basis and 0.05 to 3 wt. % light-shielding agent based on the main ingredient.

10 . A tablet as claimed in claim 9 , which contains 0.01 to 1 wt. % plasticizer based on the main ingredient in a coating layer.

11 . A tablet as claimed in any one of claim 1 to 4 , which consists of a plain tablet containing 10 to 50 wt. % excipient selected from the group of lactose, corn starch, and crystalline cellulose, 5 to 40 wt. % disintegrator selected from the group of carmellose calcium, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone, 1 to 10 wt. % binder selected from the group of hydroxypropylcellulose and polyvinylpyrrolidone, and 0.5 to 5 wt. % lubricant selected from the group of magnesium stearate and talc on the main ingredient, and a coating layer containing 2 to 6 wt. % coating basis selected from the group of hydroxypropylmethylcellulose and hydroxypropylcellulose, 0.01 to 1 wt. % plasticizer selected from the group of triethyl citrate and triacetin, and 0.05 to 3 wt. % light-shielding agent selected from the group of titanium oxide and ferric oxide based on the main ingredient.

12 . A tablet as claimed in claim 11 , which consists of a plain tablet containing 10 to 50 wt. % lactose, 5 to 40 wt. % carmellose calcium, 1 to 10 wt. % hydroxypropylcellulose, and 0.5 to 5 wt. magnesium stearate on the main ingredient, and a coating layer containing 2 to 6 wt. % hydroxypropylmethylcellulose, 0.01 to 1 wt. % triethyl citrate and 0.05 to 3 wt. % titanium oxide based on the main ingredient.

13 . A tablet as claimed in any one of claim 1 to 4 , which consists of a plain tablet containing 20 to 30 wt. % excipient selected from the group of lactose, corn starch, and crystalline cellulose, 7.5 to 15 wt. % disintegrator selected from the group of carmellose calcium, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone, 2 to 5 wt. % binder selected from the group of hydroxypropylcellulose and polyvinylpyrrolidone, and 0.5 to 3 wt. % lubricant selected from the group of magnesium stearate and talc on the main ingredient, and a coating layer containing 2 to 4 wt. % coating basis selected from the group of hydroxypropylmethylcellulose and hydroxypropylcellulose, 0.01 to 1 wt. % plasticizer selected from the group of triethyl citrate and triacetin, and 0.8 to 3 wt. % titanium oxide as a light-shielding agent based on the main ingredient.

14 . A tablet as claimed in claim 13 , which consists of a plain tablet containing 20 to 30 wt. % lactose, 7.5 to 15 wt. % carmellose calcium, 2 to 5 wt. % hydroxypropylcellulose, and 0.5 to 3 wt. magnesium stearate on the main ingredient, and a coating layer containing 2 to 4 wt. % hydroxypropylmethylcellulose, 0.01 to 1 wt. % triethyl citrate and 0.8 to 3 wt. % titanium oxide based on the main ingredient.

Assignments (3)
CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS Recorded Jul 27, 2018
From: INTERMUNE, INC.
To: INTERMUNE, INC.
Reel/Frame 046638/0466 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: KIYONAKA, GAKUJI; FURUYA, YOSHIHIRO; SUZUKI, YUSUKE
To: SHIONOGI & CO., LTD.
Reel/Frame 037935/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: SHIONOGI & CO., LTD.
To: INTERMUNE, INC.
Reel/Frame 037935/0395 →